Jazz Enters Oncology Market With EUSA Acquisition
Jazz strays away from its CNS focus with a $700 million acquisition of EUSA Pharma, adding the specialty pharma’s oncology product to its portfolio.
Jazz strays away from its CNS focus with a $700 million acquisition of EUSA Pharma, adding the specialty pharma’s oncology product to its portfolio.